RxDoctor Payments DataLook up a doctor →

Satish Gaddam

Neurology · Fort Smith, ARNPI 1023301819

Payments from drug & device makers

$13,855in general payments, 2019–2025

Across 473 payments — averaging $29.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • MDD US Operations, LLC$6K
  • AbbVie$2K
  • Abbott$529
  • Teva Pharmaceuticals USA, Inc.$377
  • Boston Scientific$366
  • Amgen$344
  • plus $5K from 52 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
MDD US Operations, LLC28$5,635
AbbVie(2 entities)104$1,625
Abbott14$529
Teva Pharmaceuticals USA, Inc.21$377
Boston Scientific5$366
Amgen(2 entities)17$344
Kyowa Kirin, Inc.18$337
Amneal Pharmaceuticals LLC16$265
Biogen14$260
Neurocrine Biosciences, Inc.14$259
Ipsen Biopharmaceuticals, Inc13$258
UCB, Inc.17$255
Avion Pharmaceuticals18$253
Acadia Pharmaceuticals Inc7$198
Novartis12$197
Medtronic(2 entities)5$193
Sunovion Pharmaceuticals Inc.14$193
Lilly USA, LLC10$165
Biohaven Pharmaceutical Holding Company Ltd.9$152
Lundbeck LLC10$151
AstraZeneca(2 entities)6$133
Adamas Pharmaceuticals, Inc.7$132
Biohaven Pharmaceuticals, Inc.9$129
Genentech USA, Inc.6$124
Sanofi7$116
Pfizer6$103
Avanir Pharmaceuticals, Inc.7$91
Eisai Inc.5$85
SK Life Science, Inc.4$83
Supernus Pharmaceuticals, Inc.5$76
Acorda Therapeutics, Inc3$68
Argenx US, Inc.3$61
Tanabe Pharma America, Inc.3$52
GE HealthCare3$48
Bristol Myers Squibb3$44
Corium, LLC3$39
Mallinckrodt Enterprises LLC2$35
Sumitomo Pharma America, Inc.2$34
Scilex Pharmaceuticals Inc.2$34
Arbor Pharmaceuticals, Inc.2$34
Aprecia Pharmaceuticals, LLC2$29
Alnylam Pharmaceuticals Inc.1$27
Arteriocyte Medical Systems, Inc.1$26
Assertio Therapeutics, Inc.1$23
Impel Pharmaceuticals Inc.1$21
Grifols USA, LLC1$20
Alfasigma USA, Inc.1$18
CSL Behring1$17
Vertical Pharmaceuticals, LLC1$17
Currax Pharmaceuticals LLC1$17
Otsuka America Pharmaceutical, Inc.1$16
Aquestive Therapeutics, Inc.1$15
TG Therapeutics, Inc.1$14
Takeda Pharmaceuticals U.S.A., Inc.1$14
Neurelis, Inc.1$13
Greenwich Biosciences, Inc.1$13
Johnson & Johnson1$12
Banner Life Sciences, LLC1$12

How this compares

$13,855 in reported general payments places this provider in the 70th percentile of 93 neurology providers in Arkansas.

See all neurology providers in Arkansas

Medicare billing

Part B allowed, 2024
$4,902
Medicare patients
43
Services billed
48

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in Fort Smith

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →